Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53

British Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 233-239

  Ambs, S ^a   Bennett, W P ^a   Merriam, W G ^a   Ogunfusika, M O ^a   Oser, S M ^a   Khan, M A ^a   Jones, R T ^b   Harris, C C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Lung cancer; Tumour suppressor gene

Indexed keywords

NITRIC OXIDE SYNTHASE; PROTEIN P53; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

EID: 0031811837     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.470     Document Type: Article

References (38)

1. Agani F, Kirsch DG, Friedman SL, Kaslan MB and Semenza GL (1997) p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene Cancer Res 57: 4474-4477
2. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR and Dvorak HF (1993) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735
3. Dameron KM, Volpert OV, Tainsky MA and Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-L Science 265: 1582-1584
4. Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4-6
5. Fontanini G, Vignali S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chine S, Silvestri V, Angeletti CA, Basolo F and Bevilacqua G (1997a) Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 75: 1295-1301
6. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G (1997b) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865
7. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Billiar TR and Harris CC (1996) Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53. Proc Natl Acad Sci USA 93: 2442-2447
8. Forstermann U and Kleinert H (1995) Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 352: 351-364
9. Forsythe JA, Jiang BH, lyer NV, Agani F, Leung SW, Koos RD and Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor I. Mol Cell Biol 16: 4604-4613
10. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4875
11. Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB and Erzurum SC (1995) Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci USA 92: 7809-7813
12. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364
13. Harris AL (1997) Antiangiogenesis for cancer therapy. Lancet 349: 13-15
14. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC and Moncada S (1995) Roles of nitric oxide in tumour growth. Proc Natl Acad Sci USA 92: 4392-4396
15. Kang S-M, Maeda K, Onoda N, Chung Y-S, Nakata B, Nishiguchi Y and Sowa M (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumour vascularity and liver metastasis. Int J Cancer 74: 502-507
16. Kieser A, Weich HA, Brandner G, Marme D and Kolch W (1994) p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969
17. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844
18. Kobzik L, Bredt DS, Lowenstein CJ, Drazen J, Gaston B, Sugarbaker D and Stamler JS (1993) Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 9: 371-377
19. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ and Joreano JL (1996) Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56: 5391-5396
20. Lehman TA, Bennett WP, Metcalf RA, Reddel R, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, Gerwin BI and Harris CC (1991) p53 mutations, ras mutations and p53-heat shock 70 protein complexes in human lung cell lines. Cancer Res 51: 4090-4096
21. Maeda H, Noguchi Y, Sato K and Akaike T (1994) Enhanced vascular permeability in solid tumour is mediated by nitric oxide and inhibited by both new nitric oxide seavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 85: 331-334
22. Mattern J, Koomagi R and Volm M (1995) Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Cancer 6: 1059-1062
23. Mazure NM, Chen EY, Yeh P, Laderoute KR and Giaccia, AJ (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56: 3436-3440
24. Melillo G, Musso T, Sica A, Taylor LS, Cox GW and Varesio L (1995) A hypoxiaresponsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182: 1683-1693
25. Millauer B, Shawver LK, Plate KH, Risau W and Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579
26. Mukhopadhyay D, Tsiokas L and Sukhatme VP (1995) Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165
27. Plate KH, Breier G, Weich HA, Mennel HD and Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529
28. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T and Kerbel RS (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumour angiogenesis. Cancer Res 55: 4575-4580
29. Rodenhuis S and Slebos RJ (1992) Clinical significance of ras oncogene activation and smoking in adenocarcinoma of human lung. Cancer Res 52(suppl. 9): 2665s-2669s
30. Salter M, Knowles RG and Moncada S (1991) Widespread tissue distribution. species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett 291: 145-149
31. Shweiki D, Itin A, Soffer D and Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
32. Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y and Ueda R (1991) The p53 gene is very frequently mutated in small-cell lung cancer with a distinet nucleotide substitution pattern. Oncogene 6: 1775-1778
33. Takahashi Y, Kitadai Y, Bucana, CD, Cleary KR and Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968
34. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V and Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54: 1352-1354
35. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41-44
36. Thomsen LL, Scott JMJ, Topley P, Knowles RG, Keerie AJ and Frend AJ (1997) Selective inhibition of inducible nitric oxide synthase inhibits tumour growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res 57: 3300-3304
37. Tozer GM, Prise VE and Chaplin DJ (1997) Inhibition of nitric oxide synthase induces a selective reduction in tumour blood flow that is reversible with L-arginine. Cancer Res 57: 948-955
38. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ and Bicknell R (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99: 2625-2634